Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score

BMC Nephrol. 2018 Aug 22;19(1):212. doi: 10.1186/s12882-018-1000-8.


Background: Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To assess this hypothesis we measured T50 in kidney transplant recipients participating in a randomized study comparing paricalcitol versus no treatment during the first year after kidney transplantation.

Methods: Stored serum samples from 76 kidney transplant recipients (paricalcitol n = 37, no treatment n = 39) were analyzed. Analyses were performed at inclusion (8 weeks after transplantation) and repeated one year after transplantation.

Results: There were no statistically significant differences in T50 between the paricalcitol and placebo groups, neither at baseline (p = 0.56) nor at 1 year (p = 0.61). Also, there were no significant changes in T50 over time in either group or when pooling all data (p < 0.20). In multivariate regression analysis, out of 16 potentially relevant covariates, comprising clinical and biochemical parameters, only plasma PTH and T50 at baseline were significantly correlated to T50 after one year. (p < 0.03 and p < 0.01, respectively).

Conclusions: Calcium propensity measured as T50 score remained unchanged with paricalcitol treatment in kidney transplant recipients, and was not changed over time during the study period of one year.

Trial registration:, NCT01694160 , registered 23 September 2012.

Keywords: Calcification propensity score; Paricalcitol; Randomized controlled trial; Renal transplantation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Density Conservation Agents / adverse effects
  • Calcinosis / blood*
  • Calcinosis / chemically induced
  • Calcinosis / epidemiology
  • Calcium / blood*
  • Ergocalciferols / administration & dosage*
  • Ergocalciferols / adverse effects
  • Female
  • Humans
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / trends*
  • Male
  • Middle Aged
  • Norway / epidemiology
  • Propensity Score*
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / epidemiology
  • Renal Insufficiency, Chronic / therapy


  • Bone Density Conservation Agents
  • Ergocalciferols
  • paricalcitol
  • Calcium

Associated data